DK0912192T3 - Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden - Google Patents

Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden

Info

Publication number
DK0912192T3
DK0912192T3 DK97930090T DK97930090T DK0912192T3 DK 0912192 T3 DK0912192 T3 DK 0912192T3 DK 97930090 T DK97930090 T DK 97930090T DK 97930090 T DK97930090 T DK 97930090T DK 0912192 T3 DK0912192 T3 DK 0912192T3
Authority
DK
Denmark
Prior art keywords
tumors
csf
administration
recurrence
prevent
Prior art date
Application number
DK97930090T
Other languages
English (en)
Inventor
Walter C Low
Margaret A Wallenfriedman
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of DK0912192T3 publication Critical patent/DK0912192T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97930090T 1996-06-27 1997-06-18 Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden DK0912192T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/671,251 US5837231A (en) 1996-06-27 1996-06-27 GM-CSF administration for the treatment and prevention of recurrence of brain tumors
PCT/US1997/010540 WO1997049421A1 (en) 1996-06-27 1997-06-18 Gm-csf administration for the treatment and prevention of recurrence of brain tumors

Publications (1)

Publication Number Publication Date
DK0912192T3 true DK0912192T3 (da) 2002-12-02

Family

ID=24693739

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97930090T DK0912192T3 (da) 1996-06-27 1997-06-18 Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden

Country Status (9)

Country Link
US (1) US5837231A (da)
EP (1) EP0912192B1 (da)
JP (1) JP2000515127A (da)
AT (1) ATE222769T1 (da)
AU (1) AU3400297A (da)
CA (1) CA2258608A1 (da)
DE (1) DE69715000T2 (da)
DK (1) DK0912192T3 (da)
WO (1) WO1997049421A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
JP5546084B2 (ja) * 1998-05-26 2014-07-09 オプサニテクス エルエルシー 抗原に対する免疫応答を調節する組成物および方法
AU5458500A (en) * 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
AU2001288863A1 (en) * 2000-09-15 2002-03-26 Ortho-Mcneil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
ATE422901T1 (de) * 2001-03-12 2009-03-15 Inst Of Gene And Brain Science Granulocyte-macrophage colony-stimulating factor (gm-csf) als heilmittel für nervenschäden
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20090155311A1 (en) * 2006-01-07 2009-06-18 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
JP6426001B2 (ja) * 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
US20150024008A1 (en) * 2011-11-21 2015-01-22 The University Of Chicago Methods and Compositions Involving Induced Senescent Cells for Cancer Treatment
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
DK3536334T3 (da) * 2012-05-16 2021-09-13 Stemline Therapeutics Inc Cancer stamcelle målrettede cancer vacciner
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5208022A (en) * 1988-05-19 1993-05-04 State University Of New York (Suny) Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
EP1216710B1 (en) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens

Also Published As

Publication number Publication date
CA2258608A1 (en) 1997-12-31
DE69715000T2 (de) 2003-01-02
EP0912192A1 (en) 1999-05-06
EP0912192B1 (en) 2002-08-28
AU3400297A (en) 1998-01-14
WO1997049421A1 (en) 1997-12-31
US5837231A (en) 1998-11-17
JP2000515127A (ja) 2000-11-14
DE69715000D1 (de) 2002-10-02
ATE222769T1 (de) 2002-09-15

Similar Documents

Publication Publication Date Title
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
NO994069L (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmate for anvendelse derav
IL128003A0 (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
DK0585943T3 (da) Opløselige ligander for CD40
GEP20012500B (en) Inhibitors of Protein Farnesyl Transferase
EP0841940A4 (en) METHOD FOR ISOLATING AND / OR PRESERVING DENDRITIC CELLS FOR IMMUNOTHERAPY OF PROSTATE CANCER
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
NO993654L (no) Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker
IS4978A (is) Aðferð til meðhöndlunar á stækkun blöðruhálskirtils og krabbameini í blöðruhálskirtli
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
DE69721810D1 (de) Konjugate zur behandlung von prostatakrebs
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
DE68903378D1 (de) Hemmung der zellenadhaesion.
DE69230314D1 (de) Cytokinhemmer
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
DK0971710T3 (da) Anvendelse af chelerythrin og stråling til tumorterapi
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
NO913995L (no) Inhibitorer for dannelse av tumornekrosefaktor samt fremgangsmaate og anvendelse derav
DE69217221D1 (de) Hydrochinonderivate und diese enthaltende Antioxydantien sowie Tumorinhibitoren
DK1121439T3 (da) Fremgangsmåder og præparater til inhibering af neoplastisk cellevækst
UA10740A (uk) Спосіб комбіhоваhого лікуваhhя раку шлуhку